Thomas Soloway
2017
In 2017, Thomas Soloway earned a total compensation of $2.7M as Executive Vice President and Chief Financial Officer at Audentes Therapeutics, a 484% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $151,410 |
|---|---|
| Option Awards | $2,207,274 |
| Salary | $378,525 |
| Total | $2,737,209 |
Soloway received $2.2M in option awards, accounting for 81% of the total pay in 2017.
Soloway also received $151.4K in non-equity incentive plan and $378.5K in salary.
Rankings
In 2017, Thomas Soloway's compensation ranked 4,017th out of 14,666 executives tracked by ExecPay. In other words, Soloway earned more than 72.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,017 out of 14,666 | 73rd |
Division Manufacturing | 1,412 out of 5,772 | 76th |
Major group Chemicals And Allied Products | 407 out of 2,075 | 80th |
Industry group Drugs | 315 out of 1,731 | 82nd |
Industry Biological Products, Except Diagnostic Substances | 59 out of 313 | 81st |
Source: SEC filing on April 26, 2019.
Soloway's colleagues
We found three more compensation records of executives who worked with Thomas Soloway at Audentes Therapeutics in 2017.